UK markets closed
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • FTSE 250

    22,659.42
    -20.22 (-0.09%)
     
  • AIM

    1,230.72
    +8.57 (+0.70%)
     
  • GBP/EUR

    1.1694
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.3977
    +0.0030 (+0.22%)
     
  • BTC-GBP

    24,080.24
    +1,587.91 (+7.06%)
     
  • CMC Crypto 200

    808.03
    -2.17 (-0.27%)
     
  • S&P 500

    4,249.16
    +2.72 (+0.06%)
     
  • DOW

    33,922.01
    -23.57 (-0.07%)
     
  • CRUDE OIL

    73.57
    +0.72 (+0.99%)
     
  • GOLD FUTURES

    1,787.20
    +9.80 (+0.55%)
     
  • NIKKEI 225

    28,874.89
    -9.24 (-0.03%)
     
  • HANG SENG

    28,817.07
    +507.31 (+1.79%)
     
  • DAX

    15,456.39
    -179.94 (-1.15%)
     
  • CAC 40

    6,551.07
    -60.43 (-0.91%)
     

Is Vaxart a Buy?

·3-min read
Is Vaxart a Buy?
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

In the early days of the pandemic, Vaxart (NASDAQ: VXRT) mesmerized investors after beginning development of a tablet-based, room-temperature-stable coronavirus vaccine. On Feb. 3, Vaxart announced that its oral coronavirus-vaccine candidate, VXA-CoV2-1, did not induce neutralizing antibodies after a one-dose regimen. The discrepancy here puzzled many investors since the two should be in tandem with one another, as with of the coronavirus vaccines currently on the market.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting